Unicycive Therapeutics Joins Russell Microcap® Index
July 01, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
NephroDI Therapeutics Announces Investment by Sound Bioventures to Accelerate Development of NDI-5001 as a Potential First-in-Class Therapy for Pediatric Orphan Kidney Disease
June 20, 2024 07:00 ET
|
NephroDI Therapeutics
New funding to take NDI-5001 into and through clinical proof of concept in Congenital Nephrogenic Diabetes Insipidus (NDI)New investment complements previously announced strategic corporate...
Sound Bioventures expands portfolio with new investment in US company NephroDI Therapeutics to accelerate development of NDI-5001 for pediatric orphan kidney disease
June 20, 2024 07:00 ET
|
Sound Bioventures
New funding will accelerate NephroDI’s asset, NDI-5001, into and through clinical proof of concept in Congenital Nephrogenic Diabetes Insipidus (NDI)New investment complements NephroDI’s previously...
American Kidney Fund Convenes Rare Kidney Disease Action Network to Advocate for Policies and Regulations that Help Patients with Rare Causes of Kidney Disease
June 13, 2024 13:07 ET
|
American Kidney Fund
ROCKVILLE, Md., June 13, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) is proud to announce the launch of the Rare Kidney Disease Action Network (RKDAN), a new effort that will play a...
Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
June 13, 2024 11:39 ET
|
Spherix Global Insights
EXTON, PA, June 13, 2024 (GLOBE NEWSWIRE) -- Complement 3 glomerulopathy (C3G) is a rare kidney disease that presents significant challenges for both patients and nephrologists. Currently, there are...
Purespring Therapeutics presents preclinical data at the 61st ERA Congress
May 24, 2024 10:57 ET
|
Purespring Therapeutics
Purespring Therapeutics presents preclinical data at the 61st ERA Congress Data establishes the potential of AAV gene therapy to deliver transgenes to the podocyte to replace defective genes or to...
Unicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor Conference
May 23, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Genitourinary Collaboration and Licensing Deals Analysis Report 2024 with Directory of Agreements Signed Since 2016
May 16, 2024 10:41 ET
|
Research and Markets
Dublin, May 16, 2024 (GLOBE NEWSWIRE) -- The "Genitourinary Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Genitourinary Collaboration and...
Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting
May 15, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
– OLC Demonstrates Bioequivalence to Lanthanum Carbonate – – Additional Poster Highlights Key Features of OLC as Perceived by Renal Dieticians – LOS ALTOS, Calif., May 15, 2024 (GLOBE...
Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update
May 13, 2024 16:16 ET
|
Unicycive Therapeutics, Inc.
– On Track to Provide Topline Data from the Ongoing Pivotal Clinical Trial with Oxylanthanum Carbonate (OLC) in Q2 2024 – – Multiple Presentations on OLC and UNI-494 at Prominent, Upcoming Medical...